Alternate Title
Basic Trial Information
Trial Description
     Purpose
     Eligibility
     Treatment/Intervention
Trial Contact Information
Registry Information

Alternate Title

Phase II Study of Suberoylanilide Hydroxamic Acid in Patients With Progressive, Persistent, or Recurrent Stage IB-IV Cutaneous T-Cell Lymphoma

Basic Trial Information

Trial Description

Purpose:

Suberoylanilide hydroxamic acid may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

This phase II trial is studying how well suberoylanilide hydroxamic acid works in treating patients with progressive, persistent, or recurrent cutaneous T-cell lymphoma.

Eligibility:

Eligibility criteria include the following:

• At least 18 years old
• For more information about the eligibility criteria for this trial, refer to the Health Professional version.

Final eligibility for a clinical trial is determined by the health professionals conducting the trial.

Treatment/Intervention:

Patients will receive suberoylanilide hydroxamic acid by mouth once a day. Treatment may continue for as long as benefit is shown.

Patients will be evaluated within 4 weeks and once a year thereafter.

Important:

For more details about this trial, refer to the Health Professional version of the trial summary.

If you are interested in participating in a clinical trial, contact your doctor for a referral or call a trial contact person listed below. You may see the same contact person listed at more than one site, however, if you call the number listed you can ask to speak to the study coordinator or person involved with the specific trial you are interested in. If you have questions about cancer or clinical trials, call the Cancer Information Service at 1-800-4-CANCER (1-800-422-6237). General information about clinical trials, including risks, benefits, and costs, can be found on NCI's Web site.

Trial Contact Information

Trial Lead Organizations

Jonsson Comprehensive Cancer Center at UCLA

Lauren Pinter-Brown, MD, Protocol chair		Ph: 818-364-3205 Email: lpb@ucla.edu

Registry Information
Official Title		Phase IIB Multicenter Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Advanced Cutaneous T-Cell Lymphoma
Registered in ClinicalTrials.gov		NCT00091559
Date Submitted to PDQ		2005-05-11
Information Last Verified		2007-07-30
NCI Grant/Contract Number		P30-CA16042

Back to Top